Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 10/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18227142 | 0.87 | APP (0.50) | TERTAPPFYNPSMB5MEN1 | |
| SCHEMBL16739383 | 0.85 | APP (0.50) | TERTAPPFYNPSMB5MEN1 | |
| SCHEMBL18227076 | 0.84 | DHFR (0.49) | TERTAPPFYNPSMB5MEN1 | |
| SCHEMBL18226916 | 0.82 | APP (0.47) | TERTAPPFYNPSMB5MEN1 | |
| SCHEMBL18227144 | 0.81 | TERT (0.49) | TERTAPPPSMB5MEN1KMT2A | |
| SCHEMBL18226918 | 0.80 | APP (0.47) | TERTAPPPSMB5 | |
| SCHEMBL18227073 | 0.80 | TERT (0.47) | TERTAPPPSMB5MEN1KMT2A | |
| SCHEMBL18227090 | 0.80 | APP (0.47) | TERTAPPPSMB5MEN1KMT2A | |
| SCHEMBL16739391 | 0.78 | TERT (0.49) | TERTAPPPSMB5MEN1KMT2A | |
| SCHEMBL24800995 | 0.76 | TERT (0.50) | TERTAPPFYNPSMB5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873670-B2 | Arylquinoline and analog compounds and use thereof to treat cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-01-23 | — | — | US | claimed |
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-29 | — | — | US | claimed |
| WO-2015077550-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | WO | claimed |
| US-9873670-B2 | Arylquinoline and analog compounds and use thereof to treat cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-29 | — | — | US | disclosed |
| WO-2015077550-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | CASP4, BAD, BID | TERT 971/4885APP 1086/4885FYN 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.